498 related articles for article (PubMed ID: 15180634)
1. The expression of thrombospondin-1 in benign prostatic hyperplasia and prostatic intraepithelial neoplasia is decreased in prostate cancer.
Vallbo C; Wang W; Damber JE
BJU Int; 2004 Jun; 93(9):1339-43. PubMed ID: 15180634
[TBL] [Abstract][Full Text] [Related]
2. Thrombospondins, metallo proteases and thrombospondin receptors messenger RNA and protein expression in different tumour sublines of the Dunning prostate cancer model.
Vallbo C; Damber JE
Acta Oncol; 2005; 44(3):293-8. PubMed ID: 16076702
[TBL] [Abstract][Full Text] [Related]
3. PTOV1 expression predicts prostate cancer in men with isolated high-grade prostatic intraepithelial neoplasia in needle biopsy.
Morote J; Fernández S; Alaña L; Iglesias C; Planas J; Reventós J; Ramón Y Cajal S; Paciucci R; de Torres IM
Clin Cancer Res; 2008 May; 14(9):2617-22. PubMed ID: 18451224
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical study of the expression of epidermal growth factor receptor in benign prostatic hypertrophy, prostatic intraepithelial neoplasia and prostatic carcinoma.
Rana S; Sen R; Kalra R; Arora B; Sharma P; Gahlawat S
Indian J Pathol Microbiol; 2006 Oct; 49(4):495-9. PubMed ID: 17183836
[TBL] [Abstract][Full Text] [Related]
5. Differential up-regulation of erythropoietin and its receptor in benign and malignant prostatic tissue.
Xu C; Zhou T; He M; Sun Y
Urol Oncol; 2010; 28(3):314-9. PubMed ID: 19070519
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer antigen-1 as a potential novel marker for prostate cancer.
Liu BQ; Wu YD; Li PH; Wei JX; Zhang T; Liu RL
Asian J Androl; 2007 Nov; 9(6):821-6. PubMed ID: 17968469
[TBL] [Abstract][Full Text] [Related]
7. Microvessel density as a molecular marker for identifying high-grade prostatic intraepithelial neoplasia precursors to prostate cancer.
Sinha AA; Quast BJ; Reddy PK; Lall V; Wilson MJ; Qian J; Bostwick DG
Exp Mol Pathol; 2004 Oct; 77(2):153-9. PubMed ID: 15351240
[TBL] [Abstract][Full Text] [Related]
8. Expression of androgen receptor and growth factors in premalignant lesions of the prostate.
Harper ME; Glynne-Jones E; Goddard L; Mathews P; Nicholson RI
J Pathol; 1998 Oct; 186(2):169-77. PubMed ID: 9924433
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue.
Hobisch A; Rogatsch H; Hittmair A; Fuchs D; Bartsch G; Klocker H; Bartsch G; Culig Z
J Pathol; 2000 Jul; 191(3):239-44. PubMed ID: 10878544
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of erythropoietin receptor in human prostate carcinoma and high-grade prostatic intraepithelial neoplasia.
Zhou T; Xu C; He M; Sun Y
Prostate Cancer Prostatic Dis; 2008; 11(2):143-7. PubMed ID: 17637760
[TBL] [Abstract][Full Text] [Related]
11. Appearance of angiotensin II expression in non-basal epithelial cells is an early feature of malignant change in human prostate.
Louis SN; Wang L; Chow L; Rezmann LA; Imamura K; MacGregor DP; Casely D; Catt KJ; Frauman AG; Louis WJ
Cancer Detect Prev; 2007; 31(5):391-5. PubMed ID: 18031950
[TBL] [Abstract][Full Text] [Related]
12. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer.
Hermani A; Hess J; De Servi B; Medunjanin S; Grobholz R; Trojan L; Angel P; Mayer D
Clin Cancer Res; 2005 Jul; 11(14):5146-52. PubMed ID: 16033829
[TBL] [Abstract][Full Text] [Related]
13. STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score.
Gomes IM; Arinto P; Lopes C; Santos CR; Maia CJ
Urol Oncol; 2014 Jan; 32(1):53.e23-9. PubMed ID: 24239460
[TBL] [Abstract][Full Text] [Related]
14. Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium.
Zhang W; Kapusta LR; Slingerland JM; Klotz LH
Cancer Res; 1998 Feb; 58(4):619-21. PubMed ID: 9485010
[TBL] [Abstract][Full Text] [Related]
15. Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer.
Segawa Y; Yoshimura R; Hase T; Nakatani T; Wada S; Kawahito Y; Kishimoto T; Sano H
Prostate; 2002 May; 51(2):108-16. PubMed ID: 11948965
[TBL] [Abstract][Full Text] [Related]
16. Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia.
Kwak C; Jin RJ; Lee C; Park MS; Lee SE
BJU Int; 2002 Feb; 89(3):303-9. PubMed ID: 11856116
[TBL] [Abstract][Full Text] [Related]
17. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
18. Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics.
Dai B; Kong YY; Ye DW; Ma CG; Zhou X; Yao XD
BJU Int; 2009 Oct; 104(7):1009-16. PubMed ID: 19389013
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of MSX2 in nodular hyperplasia, high-grade prostatic intraepithelial neoplasia and prostate adenocarcinoma.
Chua CW; Chiu YT; Yuen HF; Chan KW; Wang X; Ling MT; Wong YC
APMIS; 2010 Dec; 118(12):918-26. PubMed ID: 21091772
[TBL] [Abstract][Full Text] [Related]
20. Fas and Fas ligand expression is elevated in prostatic intraepithelial neoplasia and prostatic adenocarcinoma.
Jiang J; Ulbright TM; Zhang S; Eckert GJ; Kao C; Gardner TA; Koch MO; Eble JN; Cheng L
Cancer; 2002 Jul; 95(2):296-300. PubMed ID: 12124829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
